Paliperidon Sandoz (Paliperidone Palmitate)

Paliperidone palmitate works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors in the brain, which helps to balance neurotransmitter activity associated with psychosis. The depot formulation releases the drug slowly after an intramuscular injection, providing steady plasma levels over weeks.

The specific dose and dosing interval of Paliperidon Sandoz are determined by the prescribing clinician based on the patient’s clinical condition, prior treatment response, and tolerability. The prescriber will select the appropriate injection strength and schedule.

Safety of paliperidone palmitate in pregnancy or while breastfeeding has not been fully established. Clinicians should weigh potential benefits against risks and discuss alternative options with the patient. Women who are pregnant, planning pregnancy, or nursing should consult their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Paliperidon Sandoz (paliperidone palmitate) is a long‑acting injectable atypical antipsychotic similar to risperidone microspheres but offers a once‑monthly dosing schedule and a distinct receptor binding profile. Compared with older depot antipsychotics, it generally has a lower propensity for prolactin elevation and may provide better metabolic tolerability.

Paliperidon Sandoz should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain stability.

The medication is supplied as a sterile suspension for intramuscular injection. A healthcare professional administers the dose into the deltoid or gluteal muscle using a pre‑filled syringe or vial, following the dosing schedule prescribed by the clinician.

Serious risks include tardive dyskinesia, neuroleptic malignant syndrome, severe hyperglycaemia, orthostatic hypotension, seizures, and agranulocytosis. Patients should be monitored regularly for early signs of these conditions, and treatment should be discontinued if any severe adverse reaction occurs.

Paliperidon Sandoz is contraindicated in individuals with known hypersensitivity to paliperidone, its salts, or any formulation excipients. It should also be avoided in patients with uncontrolled severe cardiovascular disease, significant hepatic impairment, or those currently receiving strong CYP3A4 inducers without appropriate dose adjustment.